PSG9 and breast carcinoma: In line with these results, survival analyses of multiple publicly available datasets, including E‐MTAB‐365,41 GSE9195,42 GSE25066,40 and GSE11121,43 revealed that high PSG9 expression was associated with poor relapse‐free survival and distant metastasis‐free survival of patients with breast cancer (Figure S3A,B).